ES2722431T3 - Novedosos compuestos de aril-cianoguanidina - Google Patents

Novedosos compuestos de aril-cianoguanidina Download PDF

Info

Publication number
ES2722431T3
ES2722431T3 ES15807653T ES15807653T ES2722431T3 ES 2722431 T3 ES2722431 T3 ES 2722431T3 ES 15807653 T ES15807653 T ES 15807653T ES 15807653 T ES15807653 T ES 15807653T ES 2722431 T3 ES2722431 T3 ES 2722431T3
Authority
ES
Spain
Prior art keywords
group
novel aryl
ocf3
och3
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15807653T
Other languages
English (en)
Inventor
Jeffrey Stuart Mowat
Timo Stellfeld
Carlo Stresemann
Roman Hillig
Silke Köhr
Detlef Stöckigt
Jörg Weiske
Thomas Brumby
Naomi Barack
Clara Christ
Laak Antonius Ter
Volker Badock
Rosemary Helen Crampton
Ian Stefanuti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2722431T3 publication Critical patent/ES2722431T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula general (I) **(Ver fórmula)** en la que R1 representa un grupo alquilo C1-C6, que está sustituido con un sustituyente seleccionado entre -OH, -NH2 o - NHCH3, R2 representa un átomo de hidrógeno, un metilo o un grupo etilo, R3 representa un átomo de flúor o cloro, o un grupo metilo, R4 representa un grupo seleccionado entre: -CF3, -CH2CF3, -OCH3, -OCHF2, -OCF3, -OCH2CF3 u - OCH2CH2N(CH3)2, R5 representa un átomo de flúor o cloro o un grupo seleccionado entre: -OCH3, -OCF3, **(Ver fórmula)** X representa CH o N y r representa 0 o 1, así como sus polimorfos, enantiómeros, diastereómeros, racematos, Isómeros E/Z, tautómeros, solvatos, sales y solvatos fisiológicamente aceptables de estas sales.
ES15807653T 2014-12-08 2015-12-08 Novedosos compuestos de aril-cianoguanidina Active ES2722431T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196766 2014-12-08
EP15163993 2015-04-17
PCT/EP2015/078912 WO2016091845A1 (en) 2014-12-08 2015-12-08 Novel aryl-cyanoguanidine compounds

Publications (1)

Publication Number Publication Date
ES2722431T3 true ES2722431T3 (es) 2019-08-12

Family

ID=54838348

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15807653T Active ES2722431T3 (es) 2014-12-08 2015-12-08 Novedosos compuestos de aril-cianoguanidina

Country Status (7)

Country Link
US (1) US10023539B2 (es)
EP (1) EP3230274B1 (es)
JP (1) JP2017538697A (es)
CN (1) CN107207442A (es)
CA (1) CA2969771A1 (es)
ES (1) ES2722431T3 (es)
WO (1) WO2016091845A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES
CN109778407B (zh) * 2019-02-18 2020-08-11 宁波荣昌祥服饰股份有限公司 一种抗菌面料及其制备方法
WO2020216773A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
WO2020216781A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3137611A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP4126861A1 (en) 2020-03-31 2023-02-08 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CN116327748A (zh) * 2023-04-21 2023-06-27 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103794T3 (es) 1990-01-31 1997-10-01 Du Pont Pirazolinas, pirazolidinas e hidrazinas artropodicidas.
CA2532316A1 (en) 2003-07-15 2005-01-27 Bayer Healthcare Ag Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases
DE102004061748A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidin-substituierte Pyrazoline
DE102004061751A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
DE102004061747A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophen-substituierte Pyrazoline
AR082886A1 (es) * 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
US20170342034A1 (en) 2017-11-30
CN107207442A (zh) 2017-09-26
US10023539B2 (en) 2018-07-17
CA2969771A1 (en) 2016-06-16
WO2016091845A1 (en) 2016-06-16
EP3230274B1 (en) 2019-01-30
EP3230274A1 (en) 2017-10-18
JP2017538697A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
ES2722431T3 (es) Novedosos compuestos de aril-cianoguanidina
PE20181145A1 (es) Compuestos de piridina
CO2021007056A2 (es) Nuevos compuestos heterocíclicos
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
ES2587284T3 (es) 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
MX2020004699A (es) Derivados de pirimidina como inhibidores de la activacion de pd1/pd-l1.
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
PE20161443A1 (es) Compuestos
PE20160661A1 (es) Compuesto de azapiridona y sus usos de los mismos
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY36101A (es) Herbicidas de piridazinona
AR087193A1 (es) Compuestos fungicidas 2-[2-cloro-4(4-cloro-fenoxi)-fenil]-1-[1,2,4]triazol-1il-etanol alquilo sustituidos
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
ECSP11011318A (es) Derivados de benzofurano
CO2018003367A2 (es) Benzamidas sustituidas con isoxazolina y análogos como insecticidas
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
AR099469A1 (es) Fungicidas derivados de oxoborazoles
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
MX2018003276A (es) Compuesto farmaceutico.
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR077364A1 (es) Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)